Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8866720 | 1.00 | TDP1 (1.00) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL2468143 | 1.00 | TDP1 (1.00) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL17138 | 1.00 | TDP1 (1.00) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL10564326 | 1.00 | TDP1 (1.00) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL786105 | 1.00 | TDP1 (1.00) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL9130818 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL8647927 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL456025 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL11041213 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 | |
| Pentetic Acid SCHEMBL8115532 | 0.97 | TDP1 (0.94) | TDP1BLMPMP22KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1849 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026099626-A1 | METHODS AND SYSTEMS FOR MANUFACTURING RADIOPHARMACEUTICALS | NOVARTIS AG (CH) | 2026-05-15 | — | — | WO | claimed |
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | claimed |
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-3977137-B1 | DETECTION OF ANALYTES BY NANOPORE WITHOUT USING ELECTRODES | NANJING UNIVERSITY (CN) | 2026-04-01 | — | — | EP | claimed |
| EP-4713029-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (DE) | 2026-03-25 | — | — | EP | claimed |
| EP-4713424-A1 | COMPOSITIONS WITH REDUCED SOLID HYDROXIDE ALKALINITY FOR EFFECTIVE REMOVAL OF PROTEIN SOILS AND ENZYME STABILITY THROUGHOUT MULTI-CYCLE DISPENSING | Ecolab USA Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-20110071274-A1 | IMMOBILISATION OF CHELATING GROUPS FOR IMMOBILISED METAL ION CHROMATOGRAPHY (IMAC) | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-03-24 | — | — | US | claimed |
| US-20100055897-A1 | WET CLEANING STRIPPING OF ETCH RESIDUE AFTER TRENCH AND VIA OPENING FORMATION IN DUAL DAMASCENE PROCESS | TAIWAN SEMICONDUCTOR MANUFACTURING CO., LTD. (TW) | 2010-03-04 | — | — | US | claimed |
| EP-1298970-B1 | Method for producing metal/ceramic bonding circuit board | DOWA METALTECH CO LTD (JP) | 2009-11-11 | — | — | EP | claimed |
| EP-1017427-B1 | USE OF A COMPOSITION COMPRISING A CHELATING AGENT AND AN ANTIMICROBIAL COMPOUND FOR THE TREATMENT OF BIOFILMS | UNIV TEXAS (US) | 2006-04-26 | — | — | EP | claimed |
| US-6927176-B2 | Cleaning method and solution for cleaning a wafer in a single wafer process | APPLIED MATERIALS, INC. (US) | 2005-08-09 | — | — | US | claimed |
| US-6918529-B2 | Method for producing metal/ceramic bonding circuit board | DOWA MINING CO., LTD. (JP) | 2005-07-19 | — | — | US | claimed |
| US-20030066865-A1 | Method for producing metal/ceramic bonding circuit board | DOWA MINING CO., LTD. (JP) | 2003-04-10 | — | — | US | claimed |
| EP-1298970-A2 | Method for producing metal/ceramic bonding circuit board | Dowa Mining Co., Ltd. (JP) | 2003-04-02 | — | — | EP | claimed |
| US-6267979-B1 | PROVIDINY AQUEOUS SYSTEM FORMULATION COMPRISING CHELATING AGENT, AN ANTIMICROBIAL TO CONTROL GROWTH OF MICROORGANISMS | WAKE FOREST UNIVERSITY | 2001-07-31 | — | — | US | claimed |
| US-4941926-A | TREATING THE SURFACE OF THE REACTOR WITH AN ORGANIC ACID OR SALT, ALSO A CORROSION RESISTANT AGENT, A REDUCING AGENT A PENETRANT AND WATER | HAKUTO CHEMICAL CO., LTD. (JP) | 1990-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | TDP1 4084/4885BLM 4220/4885PMP22 4608/4885 |
| US-20110071274-A1 | IMMOBILISATION OF CHELATING GROUPS FOR IMMOBILISED METAL ION CHROMATOGRAPHY (IMAC) | INHA, SLC7A1, SLC3A2 | TDP1 4162/4885BLM 3202/4885PMP22 3063/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | TDP1 4528/4885BLM 3322/4885PMP22 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.